Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2010-10-25
2011-10-04
Martinell, James (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200
Reexamination Certificate
active
08029995
ABSTRACT:
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
REFERENCES:
patent: 6692916 (2004-02-01), Bevilacqua et al.
patent: 6960439 (2005-11-01), Bevilacqua et al.
patent: 6964850 (2005-11-01), Bevilacqua et al.
patent: 7767391 (2010-08-01), Scott et al.
patent: 2001/0044414 (2001-11-01), Clark et al.
patent: 2002/0150922 (2002-10-01), Stolk et al.
patent: 2002/0172987 (2002-11-01), Terstappen et al.
patent: 2003/0077568 (2003-04-01), Gish et al.
patent: 2003/0109690 (2003-06-01), Ruben et al.
patent: 2003/0148314 (2003-08-01), Berger et al.
patent: 2003/0166064 (2003-09-01), King et al.
patent: 2003/0198970 (2003-10-01), Roberts
patent: 2003/0219760 (2003-11-01), Gordon et al.
patent: 2003/0225526 (2003-12-01), Golub et al.
patent: 2004/0053317 (2004-03-01), Glinskii et al.
patent: 2005/0014165 (2005-01-01), Lee et al.
patent: 2006/0195269 (2006-08-01), Yeatman et al.
patent: 2006/0211036 (2006-09-01), Chou et al.
patent: 2007/0105133 (2007-05-01), Clarke et al.
patent: 2007/0166704 (2007-07-01), Huang et al.
patent: 2009/0258795 (2009-10-01), Cowens et al.
patent: 2009/0305277 (2009-12-01), Baker
patent: 2010/0285980 (2010-11-01), Shak
patent: 2010/0291573 (2010-11-01), Cowens
patent: 1522594 (2005-04-01), None
patent: 1 274 865 (2007-02-01), None
patent: WO99/64626 (1999-12-01), None
patent: WO99/64627 (1999-12-01), None
patent: WO00/24940 (2000-05-01), None
patent: WO01/41815 (2001-06-01), None
patent: WO02/12280 (2002-02-01), None
patent: WO02/12328 (2002-02-01), None
patent: WO02/24956 (2002-03-01), None
patent: WO03050243 (2003-06-01), None
patent: WO03/062395 (2003-07-01), None
patent: WO2004/110345 (2004-12-01), None
patent: WO2005/000087 (2005-01-01), None
patent: WO2005/015236 (2005-02-01), None
patent: WO2005/076005 (2005-08-01), None
patent: WO 2005/100593 (2005-10-01), None
patent: WO2006/010150 (2006-01-01), None
patent: WO2006/081248 (2006-08-01), None
patent: WO2006/110581 (2006-10-01), None
patent: WO2007/061876 (2007-05-01), None
patent: WO2007/070621 (2007-06-01), None
patent: WO 2007/073220 (2007-06-01), None
patent: WO2007/112330 (2007-10-01), None
U.S. Appl. No. 12/696,934, Wayne Cowens.
U.S. Appl. No. 12/911,519, Wayne Cowens.
U.S. Appl. No. 12/911,526, Wayne Cowens.
U.S. Appl. No. 12/911,544, Wayne Cowens.
U.S. Appl. No. 12/911,551, Wayne Cowens.
Augenlicht et al., Low-level c-mycamplification in human colonic carcinoma cell lines and tumors: A frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Research 1997; 57:1769-1775.
Avvisato et al., Mechanical force modulates global gene expression and β-catenin signaling in colon cancer cells. Journal of Cell Science 2007; 120(Pt 15):2672-2682.
Collett et al., Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2006; 27(6):1285-1291.
Traka et al., Transcriptome analysis of human colon caco-2 cells exposed to sulforaphane. Journal of Nutrition 2005; 135(8):1865-1872.
Qui et al., Down-regulation of growth arrest DNA damage-inducible gene 45β expression is associated with human hepatocellular carcinoma. American Journal of Pathology 2003; 162(6):1961-1974.
Barrier et al., “Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients”, Diseases of the Colon and Rectum, 2005, 48(12):2238-2248.
Arango et al., “Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer”, Gastroenterology, 2005, 129(3):874-884.
Bertucci et al., “Gene expression profiling of primary breast carcinomas using arrays of candidate genes”, Human Molecular Genetics, 2000, 9(20):2981-2991.
Callagy et al., “Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index,” Clin. Cancer Res., 2006, 12(8):2468-2475.
Kononen J. et al., “Tissue microarrays for high-throughput molecular profiling of tumor specimens”, Nature Medicine, 1998, 4(7):844-847.
Lee M. O. et al., “Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta”, Biochemical Pharmacology, 2000, 59(5):485-496.
Modlich, O. et al., “Predictors of primary breast cancers responsiveness to preoperative Epirubicin/Cyclophosphamide-4 based chemotherapy: transition of microarray data into clinically useful predictive signatures,” Journal of Translational Medicine, 2005, 3:32.
Nakopoulou, L. et al., “Stromelysin-3 protein expression in invasive breast cancer: Relation to proliferation, cell survival and patients' outcome,” Modern Pathology, 2002, 15(11):1154-1161.
Nessling et al., “Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue,” Cancer Res., 2005, 65(2):439-447.
Rosati et al., “Thymidylate synthase expression p53 bcl-2 K1-67 and p27 in colorectal cancer: Relationships with tumor recurrence and survival”, Tumor Biology Karger Basel CH, 2004, 25(5-6):258-263.
Sarela A. I. et al., “Expression of the antiapoptosis gene surviving predicts death from recurrent colorectal carcinoma”, Gut British Medical Association, 2000, 46(5):645-650.
Sun, “Retinoic acid receptor beta and colon cancer”, Cancer Biology and Therapy, 2004, 3(1):87-88.
Urruticoechea, A. et al., “Proliferation marker in Ki-67 in early breast cancer,” Journal of Clinical Oncology, 2005, 23(28):7212-7220.
Wildi S. et al., “Overexpression of activin A in stage IV colorectal cancer”, Gut British Medical Association, 2001, 49:409-417.
Youssef E.M. et al., “Methylation and regulation of expression of different retinoic acid receptor beta isoforms in human colon cancer”, Cancer Biology and Therapy, 2004, 3(1):82-86.
Backus, H.H.J. et al., “Differential Expression of Cell Cycle and Apoptosis Related Proteins in Colorectal Mucosa, Primary Colon Tumours, and Liver Metastases,” J. Clin. Path. 55:206-211 (2002).
Barrier, A. et al., “Colon Cancer Prognosis Prediction by Gene Expression Profiling,” Oncogene 24:6155-6164 (2005).
Bertucci, F. et al., “Gene Expression Profiling of Colon Cancer by DNA microarrays and Correlation with Histoclinical Parameters,” Oncogene 23:1377-1391 (2004).
Compton, C. et al., “The Staging of Colorectal Cancer: 2004 and Beyond,” CA Cancer J. Clin. 54:295-308 (2004).
Eschrich, S. et al., “Molecular Staging for Survival Prediction of Colorectal Cancer Patients,” J. Clin. Oncol. 23:3526-3535 (2005).
Ogawa, S. et al., “The Breakdown of Apoptotic Mechanism in the Development and Progression of Colorectal Carcinoma,” Anticancer Research 24:1569-1580 (2004).
Wang, Y. et al., “Gene Expression Profiles and Molecular Markers to Predict Recurrence of Dukes' B Colon Cancer,” J. Clin. Oncol. 22:1564-1571 (2004).
Baker Joffre B.
Clark Kim
Cowens Wayne
Hackett James
Paik Soonmyung
Borden Paula A.
Bozicevic Field & Francis LLP
Genomic Health, Inc.
Martinell James
NSABP Foundation, Inc.
LandOfFree
Gene expression markers for colorectal cancer prognosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene expression markers for colorectal cancer prognosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene expression markers for colorectal cancer prognosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4301893